Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

NCT03941093 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

284

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer Non-resectable

Interventions

DRUG: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
DRUG: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

Sponsor

Kyntra Bio